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Decreased Plasma Aβ in
Hyperlipidemic APPSL Transgenic
Mice Is Associated with BBB
Dysfunction
Tina Löffler *, Stefanie Flunkert, Magdalena Temmel and Birgit Hutter-Paier
Neuropharmacology, QPS Austria, Grambach, Austria
Besides the continued focus on Aβ and Tau in Alzheimer’s disease (AD), it is increasingly
evident that other pathologic characteristics, such as vascular alterations or inflammation,
are associated with AD. Whether these changes are an initial cause for the onset of AD or
occur as a result of the disease in late stages is still under debate. In the present study, the
impact of the high-fat diet (HFD) induced vascular risk factor hyperlipidemia on Aβ levels
and clearance as well as cerebral vasculature and blood-brain barrier (BBB) integrity was
examined in mice. For this purpose, human APP transgenic (APPSL) and wildtype (WT)
mice were fed a HFD for 12 weeks. Plasma and tissues were subsequently investigated
for Aβ distribution and concentrations of several vascular markers. Decreased plasma
Aβ together with increased levels of insoluble Aβ and amyloid plaques in the brains of
HFD fed APPSL mice point toward impaired Aβ clearance due to HFD. Additionally, HFD
induced manifold alterations in the cerebral vasculature and BBB integrity exclusively
in human APP overexpressing mice but not in wildtype mice. Therefore, HFD appears
to enhance Aβ dependent vascular/BBB dysfunction in combination with an increased
proportion of cerebral to plasma Aβ in APPSL mice.
Keywords: Alzheimer’s disease, high-fat diet, cholesterol, APP mice, plasma Aβ, blood brain barrier (BBB),
cerebrovascular disorders
INTRODUCTION
With advancing age Alzheimer’s disease (AD) is the major cause of dementia. The two main
histo-pathological features of AD are the extracellular deposition of amyloid β peptides (Aβ)
in plaques and the formation of intracellular tangles mainly composed of hyperphosphorylated
Tau protein (Selkoe, 2001). Aβ is a proteolytic product of the amyloid precursor protein (APP),
generated by sequential β-secretase and γ-secretase cleavage. While in rare cases of early onset
AD the disease is caused by mutations in the genes for APP or Presenilins, the majority of late-
onset AD (LOAD) patients do not have a mutation in one of the genes (Tanzi and Bertram,
2005; Bell and Zlokovic, 2009). Therefore, cerebral accumulation of Aβ in LOAD patients is
supposed to be a result of an imbalance between increased production and decreased clearance
Abbreviations: AD, Alzheimer’s disease; Aβ, amyloid beta; APP, amyloid precursor protein; BBB, blood-brain-barrier; CAA,
cerebral amyloid angiopathy; HDL, high density lipoprotein; HFD, high-fat diet; LDL, low density lipoprotein; LOAD, late-
onset AD; LRP1, LDL-receptor-related protein 1; RAGE, receptor for advanced glycation end products; VCAM1, Vascular
Cell Adhesion Molecule 1; ZO1, Zona Occludens 1.
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of Aβ by so far unknown reasons (Hardy and Selkoe, 2002).
The current understanding implies that Aβ is released from
the brain across the blood-brain barrier (BBB) into the blood
(Podlisny et al., 1990), mainly via low density lipoprotein
receptor-related protein 1 (LRP1)-mediated clearance (Kang
et al., 2000; Shibata et al., 2000; Bates et al., 2009). Additionally,
a converse mechanism, leading to an influx of Aβ into the
brain exists that is mediated by the receptor for advanced
glycation end products (RAGE; Mackic et al., 1998; Deane
et al., 2003). Generally, the integrity of the BBB is of high
importance for maintaining healthy brain function, since it
prevents a passive exchange of solutes between the blood and
the brain. During aging and in AD, several alterations in
the cellular elements of the BBB can be observed, including:
loosening of tight junctions, accumulation of extracellular matrix
components in the vascular basement membrane, decreased
endothelial mitochondrial density and changes in the expression
of endothelial receptors/transporters (Marques et al., 2013).
Additionally, several other cerebrovascular abnormalities have
been identified in AD brains such as increased microvascular
density, increase of inflammatory markers, changes in vessel
diameter, atherosclerotic plaques and/or cerebral amyloid
angiopathy (CAA; Farkas and Luiten, 2001). It is still unclear,
whether these changes are the initial cause for the onset of AD
or occur as a result of the disease. In the last years, increasing
evidence suggests that hypercholesterolemia and other vascular
risk factors may contribute to the pathogenesis of LOAD (Skoog
et al., 1999; Humpel, 2011).
Similar to human AD tissue, various of these cerebrovascular
abnormalities like CAAs, changes in cerebral angiogenesis or
BBB integrity, were observed in different APP transgenic mouse
models (van Dooren et al., 2005; Biron et al., 2011). In the
here presented study we investigated the additional impact
of hyperlipidemia on BBB integrity as well as Aβ levels and
clearance in human APP transgenic (APPSL) and wildtype (WT)
mice. Animals received a high-fat diet (HFD) or standard diet
(ND) for 12 weeks starting at an age of 3 months. Harvested
tissues were subsequently analyzed for Aβ levels and distribution,
as well as for several vascular and BBB markers.
HFD seems to impact cerebral Aβ clearance observed
as decreased plasma Aβ with concomitantly increased levels
of insoluble Aβ and plaques in the brain of APPSL mice.
Additionally, HFD induced several changes in the cerebral
vasculature and BBB integrity in mice overexpressing mutated
human APP.
MATERIALS AND METHODS
Animals
APPSL transgenic mice (Havas et al., 2011; Löﬄer et al., 2014),
overexpressing human APP with Swedish and London mutation
by the mThy1 promoter, and non-transgenic littermates (WT)
were housed in individually ventilated cages under a constant
light-cycle (12 h light/dark). Room temperature and humidity
were kept constant at approximately 24◦C and 40–70%,
respectively. Transgenic and WT animals of both sexes were
fed either a high-fat diet (HFD – D12451 mod, see Table 1)
TABLE 1 | Diet composition of the high fat diet (HFD) in comparison to the
normal diet (ND).
Crude nutrients (%) HFD ND Fatty acids (%) HFD ND
Dry matter 93.9 94.8 C14 : 0 0.29 0.02
Crude protein 22.5 17.8 C16 : 0 5.15 0.55
Crude fat 23.1 5.1 C16 : 1 0.62 0.03
Crude fiber 5.7 5.0 C18 : 0 2.83 0.24
Crude ash 5.9 5.3 C18 : 1 8.99 1.33
N free extracts 36.8 61.9 C18 : 2 3.19 2.65
Starch 6.6 36.8 C18 : 3 0.37 0.32
Sugar 20.4 14.8 C20 : 0 0.01 0.02
Dextrin 11.1 11.0 Cholesterol (mg/kg) 175 −
or standard rodent chow (ND, both ©Ssniff, Soest, Germany)
starting at the age of 3 months and pursuing the diet for 12 weeks.
During this period, animals’ weights were recorded once weekly
to follow weight changes. Chow and normal tap water were
available ad libitum. Animal studies conformed to the Austrian
guidelines for the care and use of laboratory animals and were
approved by the legal authorities.
Tissue Sampling
To be able to obtain plasma of fasted mice, chow was removed
from the cages 4–5 h before tissue sampling. From each tested
mouse, blood and brain tissue were sampled after sedation.
Blood was collected into heparin-coated vials and consequently
used to obtain plasma (1000 × g, 10min at RT). The collection
of brain tissue was performed as described in Löﬄer et al.
(2014). Hippocampi and cortices of the left brain hemispheres
were used for biochemical analyses. The right hemispheres
of all mice were fixed by immersion in freshly produced 4%
paraformaldehyde/PBS (pH 7.4) at room temperature for 1 h,
followed by 24 h incubation in 15% sucrose/phosphate buffered
saline solution for cryo-conservation. Frozen hemispheres were
stored at−80◦C until further histological processing.
Plasma Lipid Measurements
Total cholesterol was determined by Fluitest CHOL, high density
lipoprotein (HDL) by Fluitest HDL direct and low density
lipoprotein (LDL)-cholesterol, by Fluitest LDL direct assay (all
Analyticon Biotechnologies, Lichtenfels, Germany). Plasma of all
animals was diluted 1:2 in 0.2% NaCl solution and assays were
carried out in accordance with the supplied manuals.
Homogenization of Frozen Tissue Samples
Frozen tissue samples were weighed and Tissue
Homogenization Buffer (THB; 250 mmol/L sucrose, 1
mmol/L ethylenediaminetetraacetic acid (EDTA), 1 mmol/L
ethylene glycol tetraacetic acid (EGTA), 20 mmol/L Tris, pH
7.4) including 1× protease inhibitor cocktail (Calbiochem,
Darmstadt, Germany) was added. For cortex samples, 1 mL THB
per 100mg tissue was added and for hippocampal samples, 3
mL THB was used for 100mg tissue and homogenized with the
Tissue Ruptor at greatest speed (Qiagen, Düsseldorf, Germany).
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Extraction of Non-plaque Associated
Proteins (Soluble Aβ)
For extraction of non-plaque associated proteins, 100 µl of
the THB homogenate were mixed with 100 µl diethylamine
(DEA) solution (0.4% DEA, 100 mM NaCl). The mixture was
centrifuged for 1 h at 74,200 × g, 4◦C. 170 µl of the supernatant
were transferred to a 1.5 ml reaction tube and neutralized with 17
µl 0.5 M Tris, pH 6.8.
Extraction of Deposited Proteins (Insoluble
Aβ)
For extraction of deposited proteins, 100 µl of the THB
homogenate were mixed with 220 µl cold formic acid (FA) and
sonicated for 1min on ice. 300µl of this solution were transferred
to a centrifugation tube and centrifuged for 1 h at 74,200 ×
g, 4◦C. After centrifugation, 210 µl of the supernatant were
transferred to a fresh tube andmixed with 4 ml FANeutralization
Solution (1 M Tris, 0.5 M Na2HPO4, 0.05% NaN3).
Measurement of Aβ in Cortical and Plasma
Samples
Plasma and cortical samples (DEA and FA fraction) of all groups
were analyzed for Aβ1−38, Aβ1−40 and Aβ1−42 with MSD
R©
96-well MULTI-SPOT R© 4G8 Abeta Triplex Assay (Mesoscale
Discovery, Rockville, USA). The immunosorbent assay was
carried out according to the manual and plates were analyzed on
the Sector Imager. The assay detects human as well as rodent Aβ
species.
Semi-quantitative ELISA
For all ELISA measurements, samples were diluted in carbonate-
bicabonate buffer pH 9.5, 30 µl were added to each well of a
NUNC Maxi-Sorp 96 well plate (Thermo Scientific, Waltham,
USA) and incubated overnight at 4◦C without agitation. Plates
were then washed three times with 250 µl/well of ELISA-wash
buffer (50 mM Tris, 0.14 M NaCl, 0.05% Tween-20, pH 8.0)
and blocked for 30 min with 100 µl blocking buffer (50 mM
Tris, 0.14 M NaCl, 1% BSA, pH 8.0). After blocking, plates
were washed once and 40 µl of the respective primary antibody
diluted in blocking buffer + 0.05% Tween-20 were added and
incubated while shaking for 2 h at room temperature (RT). Plates
were again washed three times and 40 µl of the corresponding
horseradish-peroxidase (HRP)-conjugated secondary antibody
were added. After 1 h incubation at RT on a plate shaker,
plates were washed three times and 100 µl of ultrasensitive TMB
substrate (Applied Biological Materials Inc., Richmond, Canada)
were added. After 30 min incubation in the dark, reaction was
stopped with 100 µl 0.5 M H2SO4 and measured at 450 nm
with µQuant universal microplate spectrophotometer. Relative
differences between groups were expressed as x-fold change to
WT on normal diet (ND). To be in a linear range, optimal
dilutions of antibodies and samples were tested prior to the
measurements. Antibodies: anti-mouse IgG biotinylated (Eubio,
BA-2000; 1:5000) + anti-streptavidin HRP conjugated (Zymed,
43-4323; 1:5000); anti-occludin (abcam, ab167161; 1:1000) +
anti-rabbit IgG, HRP-linked (GE-Healthcare, NA934; 1:5000);
anti-ZO1 tight junction protein (abcam, ab59720; 1:100) +
anti-rabbit IgG, HRP-linked (GE-Healthcare, NA934; 1:2500);
anti-Vascular Cell Adhesion Molecule 1 (VCAM-1) (Santa
Cruz, sc-1504-R; 1:500) + anti-rabbit IgG, HRP-linked (GE-
Healthcare, NA934; 1:5000); anti-LRP1 [alpha-2-macroglobulin
receptor] (Santa Cruz, sc-57351; 1:500) + anti-mouse IgG,
peroxidase linked (GE-Healthcare, NA931; 1:1000); anti-Cluster
of Differentiation 31 (CD31) (abcam, ab28364; 1:250) + anti-
rabbit IgG, HRP-linked (GE-Healthcare, NA934; 1:1000).
Immunoblotting
Equal amounts of protein were separated on a 10% SDS-
polyacrylamide gel and transferred onto a 0.45 µm nitrocellulose
membrane using a wet blot chamber (Bio-Rad, Hercules,
USA). The blots were incubated overnight with the primary
antibody at 4◦C. Proteins were detected using Western-Bright
ECL spray (Advansta, Menlo Park, USA) after incubation
for 1 h at room temperature with the appropriate secondary
antibody. Primary antibodies used: anti-ZO1 tight junction
protein (abcam, ab59720; 1:100); anti-Vascular Cell Adhesion
Molecule 1 (VCAM-1) (Santa Cruz, sc-1504-R; 1:500). Secondary
antibody: anti-rabbit IgG, HRP-linked (GE-Healthcare, NA934;
1:5000).
Immunofluorescence
From every group 4 animals were randomly chosen for
histological examination. Cryo-conserved brains were embedded
in O.C.T. tissue freezing medium (Leica biosystems, Nussloch,
Germany) and cut sagittally from the medial to the lateral
side. The brain was divided into 12 layers, each containing 30
slices á 10 µm thick, according to the mouse brain atlas of
Paxinos & Franklin 2nd edition. Five 10-µm-thick mounted
sections deriving from five different medio-lateral levels (L2, 4,
6, 8, and 11) per animal were labeled using specific antibodies.
In brief, for quantification of plaque load, sections were
labeled with 6E10 antibody (Signet, 9320-02, 1:1000), detected
with a Cy3 conjugated goat anti-mouse antibody (Jackson,
115-165-166, 1:500). The boundaries of the entire hippocampus
and cerebral cortex gray matter were delineated and measured
and immunoreactive area within each region was quantified
above threshold and a minimal size of 7 µm2 using rater-
independent automated image analysis software (Image Pro
Plus, version 6.2) relative to the respective region size. For
quantification of vascular density and vascular Aβ, sections
were co-stained with antibodies detecting collagen IV (anti-
collagen IV, abcam, ab6586, 1:700) and Aβ40/42 (anti-Aβ
protein MOAB2, Biosensis, M-1586-100, 1:1000) and detected
with anti-rabbit IgG conjugated with Alexa Fluor 555 (abcam,
ab150066, 1:500) and anti-mouse IgG conjugated with DyLight
650 (abcam, ab98797, 1:500), respectively. Again, areas of interest
were the entire cerebral cortex and hippocampus gray matter.
Labeling was then quantified by threshold-based detection.
For quantification of exclusively vascular Aβ, collagen IV was
measured using a fill holes option and a counting bi-level mask
was saved. The inverted mask was mathematically subtracted
from the Aβ40/42 channel to allow a separate Aβ detection on
exclusively collagen IV-positive vasculature.
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RESULTS
Implication of HFD on Body Weight and
Plasma Cholesterol Level
WT mice responded to HFD feeding with a significant increase
in weight gain and plasma total cholesterol, HDL- and LDL-
cholesterol levels (Figure 1) compared to WT mice on ND. In
APPSL transgenic animals, also a tendency to increased weight
gain and higher cholesterol levels on HFD was observed, but
lacking significance (Figure 1).
Changes in the Amount and Distribution of
Cerebral and Plasma Aβ Levels
Three Aβ species, Aβ1−38, Aβ1−40, and Aβ1−42, were measured
in the plasma and cortex of all animals on both diets using an
immunosorbent assay which detects human and rodent Aβ. Due
to overexpression of mutated human APP, all Aβ species were
found to be profoundly increased in APPSL mice compared to
WT animals only expressing endogenous Aβ. In the plasma,
Aβ1−40 was the most abundant Aβ species in APPSL as well as
WT mice (Figures 2A,B). HFD led to a profound decrease of
Aβ1-40 and Aβ1-42 levels in plasma of APPSL mice at about
50 and 70%, respectively (Figure 2A). WT mice also showed a
tendency toward reduced plasma Aβ1-40 levels (Figure 2B), but
this effect was not significant. While in cortical soluble fractions
no differences between diets were observed (Figures 2C,D),
insoluble Aβ1-40 andAβ1-42 levels were found to be significantly
increased in HFD fed APPSL mice compared to APPSL mice on
ND (Figure 2E). In WT mice, diet had no significant effect on
levels of any cerebral Aβ species (Figures 2D,F).
To further define the allocation of cerebral Aβ in APPSL mice,
immunofluorescent evaluation of vascular Aβ and plaque load
was carried out. HFD led to a highly significant increase in both,
FIGURE 1 | Impact of HFD on weight gain and plasma cholesterol
levels. Comparison of final weight gain due to different diets in APPSL and WT
mice (A). Total cholesterol (B), LDL- (C), and HDL-cholesterol (D) levels in the
plasma of HFD and ND fed animals of both genotypes. N = 5–8 animals per
group. Statistical analyses: Two-way-ANOVA with Bonferroni’s post-test,
*p < 0.05.
Aβ at the cerebral microvasculature as well as plaque load in the
cortex and hippocampus of APPSL transgenic mice (Figure 3).
Alterations of Vascular Integrity due to
Genotype and/or HFD
To investigate the permeability of the BBB and the condition of
tight junctions, protein levels of total IgG, occludin and Zona
Occludens 1 (ZO1) in cortices of all animals were determined.
HFD led to a significantly increased influx of IgG into the
cortex of APPSL mice compared to ND fed APPSL mice, while
in WT mice only a tendency to higher IgG influx due to
HFD was observed (Figure 4A). Occludin levels were only
slightly decreased due to HFD in both, APPSL and WT mice
(Figure 4B). In contrast, levels of ZO1 seemed to be rather
dependent on the genotype than on the diet. Already on ND,
ZO1 showed a tendency to be reduced in APPSL mice compared
to WT on ND (Figure 4C). This difference turned significant
when comparing APPSL mice on HFD with WT mice on HFD
(Figure 4C). Expression of the low density lipoprotein receptor-
related protein 1 (LRP1) that is involved in receptor-mediated
flux of Aβ across the BBB, was also found to be mainly dependent
on the genotype (Figure 4D). Already on ND, levels of LRP1
were found to be significantly decreased in APPSL mice compared
to WT control mice (Figure 4D). Levels of CD31, a general
marker for endothelial cells and angiogenesis, showed a quite
different profile. While on ND levels of CD31 even showed a
tendency to be increased in APPSL compared to WT mice, this
picture changed completely on HFD (Figure 4E). In WT mice,
HFD induced a significant increase in CD31 levels compared
to ND leading to a highly significant difference in CD31 levels
betweenWTmice onHFD and APPSL mice onHFD (Figure 4E).
Levels of Vascular Cell Adhesion Molecule 1 (VCAM1) were
also investigated as a marker for activated ECs and inflammatory
processes and were found to be significantly increased in APPSL
mice on HFD compared to WT mice on HFD (Figure 4F).
DISCUSSION
In the last years, more and more evidence accumulates that
AD and vascular changes are linked (Pallebage-Gamarallage
et al., 2010). Multiple cerebrovascular abnormalities have been
identified in AD brains and clinical studies indicate that
individuals with vascular risk factors, like increased plasma
cholesterol, are more susceptible to AD (Puglielli et al., 2003).
Therefore, several studies were carried out investigating the
impact of different diets on APP metabolism, plaque load and
cognition in rodents (Refolo et al., 2000; Oksman et al., 2006;
Perez et al., 2010). The common outcome of these studies
suggests, that dietary alterations act on APP processing and
plaque load, either beneficial when administering high doses
of unsaturated fatty acids (Perez et al., 2010), or worsening
when treating animals with e.g., high-fat/high-cholesterol diets
(Oksman et al., 2006).
In the present study, we investigated the impact of a high-
fat/high-cholesterol diet (HFD) on cerebral Aβ levels and
distribution. Additionally we examined changes of BBB integrity
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FIGURE 2 | Impact of HFD on Aβ levels in plasma and cortex of APPSL and WT mice. Levels of Aβ1−38, Aβ1−40 and Aβ1−42 in the plasma of APPSL (A) and
WT (B) mice on HFD and ND. Cortical soluble Aβ species on HFD and ND in APPSL (C) and WT (D) mice as well as levels of cortical insoluble Aβ species on HFD and
ND in APPSL (E) and WT (F) mice. N = 5–8 animals per group. Statistical analyses: Two-way-ANOVA with Bonferroni’s post-test, *p < 0.05, *** p < 0.001.
FIGURE 3 | Immunofluorescent evaluation of vascular Aβ and amyloid plaques in HFD fed APPSL mice. Immunoreactive area (IR) of vascular Aβ in the
cortex and hippocampus of HFD and ND fed APPSL mice (A). Representative picture of vascular Aβ labeling in the cortex of a HFD fed (B) and a ND fed (C) APPSL
mouse, illustrating the overlap (yellow) between CollagenIV (green) and MOAB2 labeled Aβ (red). Scale bar: 100 µM. IR area of plaques in cortex and hippocampus of
HFD and ND fed APPSL mice (D). Representative picture of plaque load in the cortex of a HFD fed (E) and a ND fed (F) APPSL mouse, labeled with 6E10 antibody.
Scale bar: 100 µm. N = 4 animals per group. Statistical analyses: Two-way-ANOVA with Bonferroni’s post-test, *p < 0.05, **p < 0.01, ***p < 0.001.
and cerebrovascular alterations as a possible reason for the
detrimental effects of HFD. Therefore, human APP transgenic
(APPSL) and wildtype (WT) mice received a HFD or standard
diet (ND) for 12 weeks, starting at an age of 3 months. WT mice
responded very well to HFD feeding, with increased weight gain
and plasma cholesterol levels compared to ND fed WT mice. In
APPSL animals the response was weaker, lacking significance in
all measured weight- and cholesterol parameters. This influence
of cerebral APP overexpression on peripheral (lipid-) metabolism
was previously described, indicating APP as a possible sensor
for increased cholesterol levels with down regulating function
(Löﬄer et al., 2016). The current knowledge postulates that
Aβ is released from the brain into the plasma across the BBB
(Podlisny et al., 1990) mainly via LRP1 mediated transcytosis
(Kang et al., 2000; Shibata et al., 2000). Levels of different
Aβ species in the plasma have been investigated in patients as
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FIGURE 4 | Changes in protein levels of EC and BBB integrity
associated markers due to HFD and genotype measured with ELISA.
IgG influx into the cortex in APPSL and WT mice on HFD and ND (A). Cortical
levels of the tight junction markers Occludin (B) and ZO1 (C) in APPSL and WT
mice on both diets. LRP1 (D) as well as EC marker CD31 (E) and VCAM1 (F)
levels in the cortex of APPSL and WT mice on ND and HFD. Relative
differences between groups were expressed as x-fold change to WT on ND.
N = 5–8 animals per group; Statistical analyses: Two-way-ANOVA with
Bonferroni’s post-test, *p < 0.05, **p < 0.01. Additional western blots of ZO1
and VCAM1.
diagnostic markers of LOAD with contradictory results (Bates
et al., 2009). Most studies found an overlap of plasma Aβ1−40
and Aβ1−42 levels between control and AD subjects, thus limiting
its diagnostic power in human patients. In mice plasma Aβ
levels are so far poorly investigated (Van Dorpe et al., 2000;
Kandimalla et al., 2005; Galloway et al., 2007). Interestingly, in
the present study plasma Aβ1−40 and Aβ1−42 were found to be
exceedingly decreased due to HFD feeding in APPSL animals.
This effect could be due to a “lipid-masking effect,” since Aβ was
shown to be associated with lipoproteins in the plasma (Galloway
et al., 2007; Mamo et al., 2008); but in APPSL mice on ND the
highly increased plasma Aβ levels can be assumed to be brain
derived. Due to the sole neuronal expression of human APP in
these mice, Aβ found in the plasma supposably passed the BBB.
Decreased plasma Aβ levels on HFD therefore point toward a
possible clearance problem across the BBB. Together with the
high increase of all insoluble Aβ species in the brain of HFD fed
APPSL mice, impaired clearance of Aβ from the brain due toHFD
feeding can be assumed. By examining the cerebral distribution
of Aβ via immunohistochemical methods, significantly increased
plaque formation was detected. This is in line with the here
presented finding of increased insoluble Aβ species and can
also be associated with increased levels of BACE1 mRNA as
previously described (Löﬄer et al., 2016). Additionally, a high
proportion of Aβ co-localized with the cerebral vasculature was
found in HFD fed APPSL mice, suggesting that Aβ accumulates
in and around vessel walls. These results also indicate impaired
clearance mechanisms or increased Aβ influx at the BBB due
to HFD. Shibata et al. (2000) first demonstrated that LRP1 is
mainly responsible for the clearance of Aβ1−40 across the BBB.
The authors also found a reduction of LRP1 levels in human
AD brains, particularly in regions associated with extensive Aβ
deposition. In APPSL mice LRP1 levels were also found to be
significantly reduced compared to WT littermates, but the HFD
had no additional influence on LRP1 expression.
Markers associated with BBB integrity appeared to be
influenced by HFD and genotype. Tight junctions between
endothelial cells (ECs) in brain capillaries are the most important
structural elements of the BBB. BBB permeability has already
been previously described in different APP transgenic mouse
lines (Poduslo et al., 2001). In the present study, the additional
effect of HFD on BBB markers in APP transgenic vs. WT mice
became apparent. Especially the abundance of the junction-
associated protein Zona Occludens 1 (ZO1) was shown to be
significantly reduced in APPSL mice on HFD compared to WT
mice on HFD. Reduction or re-localization of the occludin-ZO1
complex from tight junctions is contributing to an increase in
paracellular permeability (Rao et al., 2002) which could also be
detected in APPSL mice on HFD observed as increased influx
of IgG into the cortex. That decreased Aβ eﬄux and increased
BBB permeability are not contradictory, but rather interrelated,
was already shown in human AD patients and in vitro studies
(Gonzalez-Velasquez et al., 2008; Hartz et al., 2012; Marques
et al., 2013). Additionally, inflammatory processes also seem to
be involved in EC dysfunction and the breakdown of the BBB
(Marques et al., 2013; Grammas et al., 2014). In the present study,
an increase in VCAM1 expression, a marker for activated ECs,
was detected in APPSL mice due to HFD. The VCAM1 protein is
known to mediate the adhesion of lymphocytes and monocytes
to ECs and therefore may also be involved in BBB disruption
(Eibl and Benoit, 2004; Priglinger et al., 2004). All these results
indicate a general slight impairment of BBB function in APPSL
mice, getting highly significant when fed a HFD.
Angiogenesis seems to be differently regulated in APPSL and
WTmice on the two applied diets. While HFD led to a significant
increase in CD31 levels in WT mice, in APPSL mice a decrease
of this angiogenesis marker was observed. This phenomenon of
increased angiogenesis due to HFD in WT mice was already
previously described (Yi et al., 2012). In contrast, reduction of
angiogenesis in HFD fed APPSL mice further completes the
picture of highly compromised cerebral vasculature in these
animals. Since almost all of the investigated BBB and vascular
markers were stronger affected in HFD fed APPSL mice than in
corresponding WT mice the influence of APP overexpression on
these parameters has to be emphasized. Although HFD was the
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triggering factor for the observed severe changes in vascular/BBB
integrity, most effects appeared only in the presence of increased
APP/Aβ levels in APPSL mice. Therefore, the often described
detrimental effects of Aβ on cerebral vasculature (Park et al.,
2004; Hartz et al., 2012) seem to be enhanced by HFD feeding
in the present study.
Since in WT mice on HFD only marginal changes in BBB
integrity could be detected, the assumption that changes in the
cerebral vasculature due to HFD feeding lead to an impaired Aβ
clearance and enhanced plaque formation should be revised. We
now hypothesize that in APP over-expressing mice HFD feeding
enhances Aβ-dependent vascular/BBB impairment, leading to
reduced Aβ clearance and hence to a higher proportion of
plaques as well as of Aβ accumulation on and around cerebral
vessels.
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